IP Verse

Sun Pharmaceutical Industries competitive analysis

Latest publications and patents of Sun Pharmaceutical Industries New

Explore the latest publications and patents granted to Sun Pharmaceutical Industries, showcasing their recent innovations and technological advancements.

Last updated on: Sep 23, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Sun Pharmaceutical Industries

EP3137060
Dec 20, 2023Extended Release Suspension CompositionsPatent Maintained As Amended
EP3811927
Feb 23, 2022A Stable Parenteral Dosage Form Of Cetrorelix AcetateGranted And Under Opposition
EP3450434
Feb 24, 2021Deuterated Derivatives Of RuxolitinibGranted And Under Opposition

Latest oppositions filed by Sun Pharmaceutical Industries

Explore patent oppositions filed by Sun Pharmaceutical Industries against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 25, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP2234617
Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICADec 27, 2021
EP2478907
Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGYSep 13, 2021

Latest patents of Sun Pharmaceutical Industries opposed by its competitors

Explore Sun Pharmaceutical Industries's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3137060
Dec 20, 2023Extended Release Suspension Compositions1
EP3811927
Feb 23, 2022A Stable Parenteral Dosage Form Of Cetrorelix Acetate1
EP3450434
Feb 24, 2021Deuterated Derivatives Of Ruxolitinib1

Latest PTAB cases involving Sun Pharmaceutical Industries

Discover the latest PTAB cases involving Sun Pharmaceutical Industries, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 29, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Sun Pharmaceutical Industries

IPR2025-00893Apr 22, 2025SUN PHARMACEUTICAL INDUSTRIESNIVAGEN PHARMACEUTICALSDiscretionary Denial
IPR2025-00287Dec 27, 2024BIOFRONTERA INCORPORATEDSUN PHARMACEUTICAL INDUSTRIESDiscretionary Denial
IPR2024-01312Aug 21, 2024BIOFRONTERA INCORPORATEDSUN PHARMACEUTICAL INDUSTRIESTrial Instituted
IPR2024-00874Apr 30, 2024BIOFRONTERASUN PHARMACEUTICAL INDUSTRIESInstitution Denied
IPR2024-00107Nov 2, 2023SUN PHARMACEUTICAL INDUSTRIESNOVO NORDISKTerminated-Settled
IPR2022-00617Feb 24, 2022SUN PHARMACEUTICAL INDUSTRIESAURINIA PHARMACEUTICALSTerminated-Settled
IPR2020-01072Jun 12, 2020SUN PHARMACEUTICAL INDUSTRIESMERCK SHARP & DOHMEFinal Written Decision
IPR2020-00822Apr 9, 2020UPJOHN 1SUN PHARMACEUTICAL INDUSTRIESTerminated-Settled
IPR2017-01929Aug 16, 2017SUN PHARMACEUTICAL INDUSTRIESNOVARTIS PHARMACEUTICALSTerminated

Peer Comparison New

IP litigation analysis comparing Sun Pharmaceutical Industries with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
SUN PHARMACEUTICAL INDUSTRIES EUROPE2 - - - Highly Aggressive
COUGAR BIOTECHNOLOGY - 22 - - Non-Active
JANSSEN ONCOLOGY - 22 - 5Non-Active
JANSSEN PHARMACEUTICA154 - 1Defensive